The study was withdrawn prior to enrollment of first participant.

A prospective, randomized, open-label, stratified, controlled clinical trial to evaluate whether long term furosemide therapy (1 year) would preserve urine volume and/or residual renal function (RRF) and improve fluid state in continuous ambulatory peritoneal dialysis (CAPD) patients.

There are 3 phases in this study. Phase 1 is screening phase. Each subject will be evaluated to determine if he/she is eligible for the study. Phase 2 is the intervention phage. Patients are divided arbitrarily into two groups according to baseline RRF (residual glomerular filtration rate [rGFR] <5or > 5 ml/min), then randomly received 12 months treatment with the study drugs( furosemide 120mg daily, 60mg daily, or no diuretic). Phase 3 is following-up phase, which lasts 1 year. Dialytic prescription is adjusted independent of the study and is guided by clinical parameters and calculated clearances (target creatinine clearance 65L/week, urea clearance Kt/V > 1.7 per week). Blood pressure is measured using an automated blood pressure device, and the target level is 135/85mmHg. The antihypertensive medication is introduced after the body weigh reduced into target level, and the ACEI and /or ARB selection is needed to the cross-sectional design. The hydration state is measured by bioelectrical impedance analysis (BIA).

Inclusion Criteria:

• Willingness to sign an informed consent
• Age:20~70 years, regardless of gender
• All patients received CAPD more than 1 months;
• Urine volume of 500ml/d or more;
• No history of taking furosemide for at least 2 weeks .

Exclusion Criteria:

• Inability or unwillingness to sign the informed consent
• Inability or unwillingness to meet the scheme demands raised by the investigators
• Current acute infection such as peritonitis ;
• Severe diarrhea or vomiting within the preceding 1 month
• Acute Cardiac failure
• Myocardial infarction within the preceding 6 months;
• Hypertensive encephalopathy or cerebrovascular accident;
• Accident within the preceding 6 months;
• Any condition, such as alcohol or drug abuse, chronic liver disease, malignant disease, or psychiatric disorder;
• Allergy or intolerance to furosemide .
• Current or recent (within 2 weeks) exposure to any other investigational drugs